Effectiveness of Omadacycline in a Patient with Chlamydia psittaci and KPC-Producing Gram-Negative Bacteria Infection

Area of Science:

• Infectious Diseases
• Pulmonology
• Pharmacology

Background:

• Community-acquired atypical pneumonia is often caused by Chlamydia psittaci.
• Prompt treatment is crucial to prevent severe pneumonia, multi-organ dysfunction, and secondary multi-drug-resistant (MDR) bacterial infections.

Observation:

• A patient presented with severe Chlamydia psittaci pneumonia and a concurrent MDR bacterial infection.
• Initial treatment with moxifloxacin and doxycycline failed, leading to clinical deterioration including leukopenia, liver dysfunction, and respiratory alkalosis.

Findings:

• Omadacycline, a novel aminomethylcycline antibiotic, demonstrated high activity against the causative pathogens.
• Switching to omadacycline therapy resulted in rapid alleviation of all complications within 48 hours.

Implications:

• Omadacycline is a promising therapeutic option for severe atypical pneumonia co-infected with MDR bacteria.
• This case highlights the potential of omadacycline in managing complex respiratory infections refractory to conventional antibiotics.